[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100518491":3},{"organization":4,"armGroups":7,"interventions":43,"overallOfficials":48,"centralContacts":65,"locations":71,"responsibleParty":87,"collaborators":48,"id":91,"slug":92,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":93,"sex":99,"minAge":100,"maxAge":48,"enrollmentInfo":101,"targetDuration":48,"studyType":104,"phases":105,"briefSummary":107,"conditions":108,"keywords":48,"overallStatus":74,"whyStopped":48,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Isala","OTHER",[8,14,18,22,26,30,34,38],{"label":9,"type":10,"description":11,"interventionNames":12},"Nivolumab","EXPERIMENTAL","If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 10 minutes in the following cycles.",[13],"Drug: Nivolumab",{"label":15,"type":10,"description":11,"interventionNames":16},"Pembrolizumab",[17],"Drug: Pembrolizumab",{"label":19,"type":10,"description":11,"interventionNames":20},"ipilimumab",[21],"Drug: Ipilimumab",{"label":23,"type":10,"description":11,"interventionNames":24},"Durvalumab",[25],"Drug: Durvalumab",{"label":27,"type":10,"description":11,"interventionNames":28},"Atezolizumab",[29],"Drug: Atezolizumab",{"label":31,"type":10,"description":11,"interventionNames":32},"bevacizumab",[33],"Drug: Bevacizumab",{"label":35,"type":10,"description":11,"interventionNames":36},"Trastuzumab",[37],"Drug: Trastuzumab",{"label":39,"type":10,"description":40,"interventionNames":41},"Rituximab","If no infusion reaction has occurred after 2 cyclues, infusion time will stepwise be shortened to 15 minutes in the following cycles.",[42],"Drug: Rituximab",[44,49,51,54,56,58,61,63],{"type":45,"name":9,"description":46,"armGroupLabels":47,"otherNames":48},"DRUG","Gradual shortening of infusion times",[9],null,{"type":45,"name":15,"description":46,"armGroupLabels":50,"otherNames":48},[15],{"type":45,"name":52,"description":46,"armGroupLabels":53,"otherNames":48},"Ipilimumab",[19],{"type":45,"name":23,"description":46,"armGroupLabels":55,"otherNames":48},[23],{"type":45,"name":27,"description":46,"armGroupLabels":57,"otherNames":48},[27],{"type":45,"name":59,"description":46,"armGroupLabels":60,"otherNames":48},"Bevacizumab",[31],{"type":45,"name":35,"description":46,"armGroupLabels":62,"otherNames":48},[35],{"type":45,"name":39,"description":46,"armGroupLabels":64,"otherNames":48},[39],[66],{"name":67,"role":68,"phone":69,"phoneExt":48,"email":70},"Elianne CS de Boer","CONTACT","+31886245000","polioncologie@isala.nl",[72],{"facility":73,"status":74,"city":75,"state":48,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":84,"contacts":85},"Isala Hospital","RECRUITING","Zwolle","8025AB","Netherlands","NL",{"type":80,"coordinates":81},"Point",[82,83],6.09444,52.5125,{"lat":83,"lon":82},[86],{"name":67,"role":68,"phone":69,"phoneExt":48,"email":70},{"type":88,"investigatorFullName":89,"investigatorTitle":90,"investigatorAffiliation":5,"oldNameTitle":48,"oldOrganization":48},"PRINCIPAL_INVESTIGATOR","HB Fiebrich-Westra","Principal Investigator","100518491","phase-4-evaluating-the-safety-of-shortened-infusion-times-for-different-oncological-immunotherapie-100518491",false,"NCT06031233","Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie","Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapies; An Observational Prospective Study","MINUTE","Inclusion Criteria:\n\n* Starting treatment with monoclonal antibodies: nivolumab, pembrolizumab ipilimumab, bevacizumab, trastuzumab, durvalumab or atezolizumab.\n* 18 years and older.\n* No known history of increased susceptibility to immunological reactions.\n* Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.\n\nExclusion Criteria:\n\n* Other research medication within 4 weeks of the start of the study.\n* Inclusion in medical research in which the administration of medication should follow its stated times and dosages of infusions\n* Dosage deviates from standard protocol\n* Patients whom receive drugs through a central venous catheter (and for example porth-a-cath).","ALL","18 Years",{"count":102,"type":103},776,"ESTIMATED","INTERVENTIONAL",[106],"PHASE4","This study is an interventional, explorative, prospective study to show whether shortening of infusion times for patients using nivolumab, pembrolizumab, ipilimumab, trastuzumab, bevacizumab, durvalumab or atezolizumab continues to be associated with an acceptable safety profile.\n\nInfusion times will be gradually shortened if tolerability allowes.",[109,110],"Oncology","Infusion Reaction","2026-03-25",{"date":113,"type":114},"2026-03-30","ACTUAL",{"date":116,"type":114},"2023-09-01",{"date":118,"type":103},"2028-12",{"name":5,"class":6},1]